Market Cap : 2.29 B | Enterprise Value : 23.33 B | PE Ratio : 54.36 | PB Ratio : |
---|
NYSE:BHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:BHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bausch Health's average Accounts Receivable for the three months ended in Jun. 2022 was $1,606 Mil. Bausch Health's Revenue for the three months ended in Jun. 2022 was $1,967 Mil. Hence, Bausch Health's Days Sales Outstanding for the three months ended in Jun. 2022 was 74.48.
The historical rank and industry rank for Bausch Health's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Bausch Health's highest Days Sales Outstanding was 99.59. The lowest was 65.75. And the median was 79.12.
BHC's Days Sales Outstanding is ranked worse thanBausch Health's Days Sales Outstanding increased from Jun. 2021 (67.53) to Jun. 2022 (74.48).
The historical data trend for Bausch Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Bausch Health's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Bausch Health's Days Sales Outstanding for the fiscal year that ended in Dec. 2021 is calculated as
Days Sales Outstanding (A: Dec. 2021 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2020 ) | + | Accounts Receivable (A: Dec. 2021 )) | / | count ) | / | Revenue (A: Dec. 2021 ) | * | Days in Period |
= | ( (1577 | + | 1775) | / | 2 ) | / | 8434 | * | 365 |
= | 1676 | / | 8434 | * | 365 | ||||
= | 72.53 |
Bausch Health's Days Sales Outstanding for the quarter that ended in Jun. 2022 is calculated as:
Days Sales Outstanding (Q: Jun. 2022 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Mar. 2022 ) | + | Accounts Receivable (A: Jun. 2022 )) | / | count ) | / | Revenue (A: Jun. 2022 ) | * | Days in Period |
= | ( (1566 | + | 1645) | / | 2 ) | / | 1967 | * | 365 / 4 |
= | 1605.5 | / | 1967 | * | 365 / 4 | ||||
= | 74.48 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Bausch Health's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Carson Seana | officer: EVP, General Counsel | 400 SOMERSET CORPORATE BLVD BRIDGEWATER NJ 08807 |
Vadaketh Tom George | officer: EVP, Chief Financial Officer | 1727 JOCKEYS WAY YARDLEY PA 19067 |
Mulligan Richard | director | C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153 |
Munsch Frederick | officer: SVP, Controller and CAO | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Gordon Joseph F | officer: Pres&Co-Head Bausch&Lomb/Int'l | 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Ackermann Christina | officer: EVP AND GENERAL COUNSEL | C/O BLCO 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Spurr Robert | director, officer: U.S. President-Pharma Business | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Eldessouky Sam | officer: EVP & Chief Financial Officer | C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Miller Steven D | director | 16690 COLLINS AVENUE PH SUNNY ISLE BEACH FL 33160 |
Icahn Brett | director | C/O ICAHN ENTERPRISES L.P. 16690 COLLINS AVE., PH SUNNY ISLES FL 33160 |
Paulson John | director | 1133 AVENUE OF THE AMERICAS 33RD FLOOR NEW YORK NY 10036 |
Valueact Holdings Ii, L.p. | director, other: See Remarks | ONE LETTERMAN DRIVE BUILDING D, FOURTH FLOOR SAN FRANCISCO CA 94129 |
Von Eschenbach Andrew C. | director | BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807 |
Mckenna Mark C. | officer: President, Salix | 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807 |
Humphries William D. | officer: EVP, COMPANY GROUP CHAIRMAN | C/O STRATA SKIN SCIENCES, INC. 5 WALNUT GROVE DRIVE SUITE 140 HORSHAM PA 19044 |
From GuruFocus
By PRNewswire 03-29-2022
Other Sources
By Zacks 2022-02-14
By Zacks 2022-01-21
By Zacks 2022-01-19
By Zacks 2022-02-08
By Zacks 2022-02-21
By Zacks 2022-02-22
By tipranks.com 2022-02-23
By Zacks 2022-03-30
By Zacks 2022-03-22
By Zacks 2022-01-31
By Seekingalpha 2022-02-23
By Zacks 2022-01-21
By Seekingalpha 2022-01-31